- **EGFR**: The article mentions EGFR amplification and the EGFRvIII variant in IDH-wildtype glioblastoma. The study by Fontanilles et al. (2020) used a digital PCR-based method to simultaneously detect EGFR amplification and the EGFRvIII variant in glioblastoma.

- **PD-L1**: The article discusses PD-L1 status as a potential biomarker in glioblastoma. Jang et al. (2020) found that a radiosensitivity gene signature and PD-L1 status could predict clinical outcomes in patients with glioblastoma multiforme.

- **MGMT**: The article extensively covers MGMT promoter methylation and its role in glioblastoma. Several studies have explored the association between MGMT protein expression, promoter methylation, and survival in glioblastoma. For instance, Schaff et al. (2020) found a weak association between MGFT protein expression and promoter methylation, and Tanguturi et al. (2017) identified associations between GBM genomic subgroups and clinical or molecular prognostic covariates.

- **PARP-1**: The article mentions PARP-1 protein expression in glioblastoma multiforme. Galia et al. (2012) investigated PARP-1 gene expression and found that it may be involved in apoptosis and genome integrity maintenance.

- **VEGFR and PDGF**: The article discusses the cross-talk between VEGF and PDGF signaling in glioblastoma. Chinnaiyan et al. (2012) hypothesized that continued VEGF inhibition could modulate PDGF-AA expression through regulatory feedback inhibition, potentially contributing to VEGF-independent progression.

- **Methylation of MGMT promoter**: The article discusses the lack of association between methylation of the MGMT promoter and molecular markers such as ATRX, IDH, p53, and Ki67 in glioblastoma. Egaña et al. (2020) found no association between methylation of the MGMT promoter and these molecular markers.

- **DGKI Methylation Status**: The article mentions DGKI methylation status as a prognostic factor in glioblastoma patients treated with combined radio-chemotherapy with temozolomide. Etcheverry et al. (2014) found that DGKI methylation status modulates the prognostic value of MGMT in glioblastoma patients receiving standard treatment.

- **mTORSer2448**: The article discusses mTORSer2448 phosphorylation as a potential biomarker in glioblastoma. Wick et al. (2016) found that phosphorylation of mTORSer2448 in pretreatment tumor tissue may define a subgroup that benefits from mTOR inhibition.

- **System A Amino Acid Transport PET Imaging with C-11-MeAIB**: The article mentions the use of C-11-MeAIB, a system A amino acid transport-specific radiolabeled agent, for the differential diagnosis between low-grade and high-grade astrocytoma. Nishii et al. (2018) found that MeAIB could provide better assessments for detecting malignant type brain tumors.

- **O6-Methylguanine–DNA Methyltransferase (MGMT)**: The article discusses MGMT as a prognostic biomarker in glioblastoma. Weller et al. (2015) found that MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma.

- **MTHFR rs1801133 Polymorphism**: The article mentions the MTHFR rs1801133 polymorphism in the context of intranasal perillyl alcohol therapy for recurrent glioblastoma. Faria et al. (2020) found that patients with the mutant variant for MTHFR rs1801133 had longer survival.

- **IDH-wildtype glioblastomas with FGFR3-TACC3 fusions**: The article discusses IDH-wildtype glioblastomas with FGFR3-TACC3 fusions and their associated mutational, copy-number, and methylation profiles. Mata et al. (2020) found that patients with FGFR3-TACC3 fusions had clinical outcomes slightly better than patients with F3T3-positive tumors.

- **BRAF(V600)-Mutant Gliomas**: The article mentions BRAF(V600)-mutant gliomas and the VE-BASKET study, which investigated BRAF inhibition in these tumors. Kaley et al. (2018) found that vemurafenib demonstrated evidence of durable antitumor activity in some patients with BRAF(V600)-mutant gliomas, although efficacy varied by histologic subtype.

- **IDH1-Mutant Solid Tumors**: The article discusses a phase I assessment of safety and therapeutic activity of BAY1436032 in patients with IDH1-mutant solid tumors. Wick et al. (2021) found that BAY1436032 was well-tolerated and showed evidence of target inhibition and durable objective responses in a small subset of subjects with LGG.

- **Oral Gimatecan for Recurrent Glioblastoma**: The article mentions a phase II trial of oral gimatecan for recurrent glioblastoma. Hu et al. (2013) found that treatment with gimatecan 1.0 mg/m2/day for 5 days, repeated every 28 days, showed minimal efficacy.

- **Dose-Intense Temozolomide in Recurrent Glioblastoma**: The article discusses a phase 2 study of dose-intense temozolomide in recurrent glioblastoma. Norden et al. (2013) found that dose-intense temozolomide on this schedule is safe, but efficacy is marginal, and predictive biomarkers are needed.

- **7 Days on/7 Days off Temozolomide for Recurrent High-Grade Glioma**: The article mentions a phase II trial of 7 days on/7 days off temozolomide for recurrent high-grade glioma. Han et al. (2014) found that the dose-dense temozolomide regimen was well-tolerated but had no significant activity in this population.

- **Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine–DNA Methyltransferase Nonmethylated Glioblastoma**: The article discusses a randomized trial comparing bevacizumab plus irinotecan (BEV+IRI) with temozolomide (TMZ) in newly diagnosed glioblastoma. Herrlinger et al. (2016) found that BEV+IRI resulted in a superior PFS-6 rate and median PFS compared with TMZ, but BEV+IRI did not improve OS, potentially due to a high crossover rate.

- **Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation**: The article discusses a phase II study comparing radiotherapy and temsirolimus with radiochemotherapy and temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation. Wick et al. (2016) found that temsirolimus was not superior to temozolomide in patients with an unmethylated MGMT promoter.

- **Hypofractionated Stereotactic Radiosurgery for High-Grade Gliomas at First Recurrence**: The article mentions a single-center experience with salvage HSRS in high-grade gliomas at first recurrence. Guan et al. (2021) found that salvage HSRS showed a favorable outcome and acceptable toxicity.

- **Scalp Sparing Radiation with Concurrent Temozolomide and Tumor Treatment Fields (SPARE) for Patients with Newly Diagnosed Glioblastoma**: The article discusses a study on scalp-sparing chemoradiation with concurrent temozolomide and tumor treatment fields (SPARE) for patients with newly diagnosed glioblastoma. Song et al. (2020) found that concurrent TTFields with scalp-sparing chemoradiation is a safe and feasible treatment option with limited toxicity.

- **Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients with Recurrent Glioblastoma**: The article discusses a randomized, double-blind, placebo-controlled, multicenter phase II study comparing onartuzumab plus bevacizumab with placebo plus bevacizumab in patients with recurrent glioblastoma. Cloughesy et al. (2017) found no evidence of further clinical benefit with the addition of onartuzumab to bevacizumab compared with bevacizumab plus placebo in unselected patients.

- **Temozolomide Plus Memantine, Mefloquine, and Metformin as Postradiation Adjuvant Therapy for Newly Diagnosed Glioblastoma**: The article discusses a phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma. Maraka et al. (2018) found that memantine, mefloquine, and metformin can be combined safely with TMZ in patients with newly diagnosed glioblastoma.

- **Two Cilengitide Regimens in Combination with Standard Treatment for Patients with Newly Diagnosed Glioblastoma and Unmethylated MGMT Gene Promoter**: The article discusses an open-label, controlled, randomized phase II CORE study investigating two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter. Nabors et al. (2015) found that both standard and intensive cilengitide dose regimens were well-tolerated, but inconsistent overall survival and progression-free survival outcomes and limited sample size did not allow firm conclusions regarding clinical efficacy.

- **Phase II Study of Bevacizumab, Temozolomide, and Hypofractionated Stereotactic Radiotherapy for Newly Diagnosed Glioblastoma**: The article discusses a phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma. Omuro et al. (2014) found that this aggressive radiotherapy schedule was safe and more convenient for patients, achieving an OS comparable to historical controls.

- **Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma**: The article discusses a phase IB study investigating immune activity and response differences of oncolytic viral therapy in recurrent glioblastoma. Miller et al. (2022) found that the oHSV-induced type I IFN production and the subsequent recruitment of an adaptive immune response differed between enrolled patients and showed an association with survival duration.

- **Multicenter Phase II Study of Temozolomide and Myeloablative Chemotherapy with Autologous Stem Cell Transplant for Newly Diagnosed Anaplastic Oligodendroglioma**: The article discusses a multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma. Thomas et al. (2017) found that TMZ followed by HDC-ASCT can be safely administered to patients with newly diagnosed 1p/19q co-deleted AO.

- **Phase 2 Study of Dose-Intense Temozolomide in Recurrent Glioblastoma**: The article discusses a phase 2 study of dose-intense temozolomide in recurrent glioblastoma. Norden et al. (2013) found that dose-intense temozolomide on this schedule is safe, but efficacy is marginal, and predictive biomarkers are needed.

- **Phase II Trial of 7 Days on/7 Days off Temozolomide for Recurrent High-Grade Glioma**: The article discusses a phase II trial of 7 days on/7 days off temozolomide for recurrent high-grade glioma. Han et al. (2014) found that the dose-dense temozolomide regimen was well-tolerated but had no significant activity in this population.

- **Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine–DNA Methyltransferase Nonmethylated Glioblastoma**: The article discusses a randomized trial comparing bevacizumab plus irinotecan (BEV+IRI) with temozolomide (TMZ) in newly diagnosed glioblastoma. Herrlinger et al. (2016) found that BEV+IRI resulted in a superior PFS-6 rate and median PFS compared with TMZ, but BEV+IRI did not improve OS, potentially due to a high crossover rate.

- **Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation**: The article discusses a phase II study comparing radiotherapy and temsirolimus with radiochemotherapy and temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation. Wick et al. (2016) found that temsirolimus was not superior to temozolomide in patients with an unmethylated MGMT promoter.

- **Clinical and Genetic Factors Associated with Severe Hematological Toxicity in Glioblastoma Patients During Radiation Plus Temozolomide Treatment**: The article discusses a prospective study investigating clinical and genetic factors associated with severe hematological toxicity in glioblastoma patients during radiation plus temozolomide treatment. Lombardi et al. (2015) suggested that clinical and genetic factors might simultaneously be associated with severe myelosuppression.

- **Phase II Study of PX-866 in Recurrent Glioblastoma**: The article discusses a phase II study of PX-866 in recurrent glioblastoma. Pitz et al. (2015) found that PX-866 was relatively well-tolerated, but the overall response rate was low, and the study did not meet its primary endpoint.

- **A Phase II Trial of Oral Gimatecan for Recurrent Glioblastoma**: The article discusses a phase II trial of oral gimatecan for recurrent glioblastoma. Hu et al. (2013) found that treatment with gimatecan 1.0 mg/m2/day for 5 days, repeated every 28 days, showed minimal efficacy.

- **International Multicenter Study for Prospective Validation of Imaging Biomarkers Calculated at Vascular Habitats of High-grade Gliomas (ALBATROSS)**: The article mentions the ALBATROSS study, which aims to prospectively validate imaging biomarkers calculated at vascular habitats of high-grade gliomas.

- **The circTeloDIAG: Liquid Biopsy for Glioma Tumor (circTeloDIAG)**: The article mentions the circTeloDIAG study, which aims to develop a liquid biopsy for glioma tumor.

- **Visual Study of Molecular Genotype in Glioma Evolution**: The article mentions a visual study of molecular genotype in glioma evolution, which aims to investigate the molecular evolution of gliomas.

- **Glioma Brain Tumours-E12513-SensiScreen Glioma**: The article mentions the Glioma Brain Tumours-E12513-SensiScreen Glioma study, which aims to develop a sensitive screening method for glioma.

- **Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy**: The article mentions a study investigating the biology of IDH-mutant gliomas via longitudinal observation of 2-hydroxyglutarate (2-HG) using MR spectroscopy.

- **Survival Significance of Molecular Pathology and Genetic Variation in Brain Gliomas**: The article mentions a study on the survival significance of molecular pathology and genetic variation in brain gliomas.

- **Evaluating the Expression Levels of MicroRNA-10b in Patients With Gliomas**: The article mentions a study evaluating the expression levels of microRNA-10b in patients with gliomas.
